edotreotide has been researched along with Cancer of Intestines in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergsma, H; de Herder, WW; Kam, BL; Krenning, EP; Kwekkeboom, DJ; Peeters, RP; Teunissen, JJ; van Vliet, EI | 1 |
| Cacciari, G; Campana, D; Capurso, G; Delle Fave, G; Falconi, M; Nori, F; Panzuto, F; Partelli, S; Tamburrino, D; Tomassetti, P | 1 |
| Habibollahi, P; Heidari, P; Kulke, M; Mahmood, U; Wehrenberg-Klee, E; Yokell, D | 1 |
| Baete, K; Deroose, CM; Haustermans, K; Koole, M; Mortelmans, L; Mottaghy, FM; Terwinghe, C; Van Binnebeek, S; Van Cutsem, E; Vanbilloen, B; Verbruggen, A; Verslype, C | 1 |
| Cybulla, M; Otte, A; Weiner, SM | 2 |
| Maecke, H; Mueller-Brand, J; Schumacher, T; Waldherr, C | 1 |
8 other study(ies) available for edotreotide and Cancer of Intestines
| Article | Year |
|---|---|
Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
Topics: Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Peptides, Cyclic; Radiopharmaceuticals; Receptors, Somatostatin; Retreatment; Somatostatin; Stomach Neoplasms; Yttrium Radioisotopes | 2012 |
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.
Topics: Aged; Female; Humans; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radiopharmaceuticals; Somatostatin; Stomach Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2013 |
Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization.
Topics: Animals; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Cell Proliferation; Chemical Fractionation; Dose-Response Relationship, Drug; Gallium Radioisotopes; Humans; Intestinal Neoplasms; Mice; Mice, Nude; Neuroendocrine Tumors; Octreotide; Prognosis; Radionuclide Imaging; Rats; Receptors, Somatostatin; Solubility; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy.
Topics: Adult; Disease Progression; Female; Humans; Indium Radioisotopes; Intestinal Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radioisotopes; Receptors, Peptide; Somatostatin; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2011 |
SNM 2012 image of the year.
Topics: Bismuth; Humans; Intestinal Neoplasms; Liver; Neuroendocrine Tumors; Nuclear Medicine; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radionuclide Imaging; Societies, Scientific; Stomach Neoplasms; Treatment Failure | 2012 |
90Y-DOTATOC and nephrotoxicity.
Topics: Animals; Carcinoid Tumor; Humans; Intestinal Neoplasms; Kidney; Kidney Failure, Chronic; Octreotide; Radiopharmaceuticals; Radiotherapy Dosage; Yttrium Radioisotopes | 2002 |
End-stage renal disease after treatment with 90Y-DOTATOC.
Topics: Aged; Carcinoid Tumor; Female; Humans; Intestinal Neoplasms; Kidney Failure, Chronic; Octreotide; Radiopharmaceuticals | 2001 |
Kidney failure after treatment with 90Y-DOTATOC.
Topics: Aged; Carcinoid Tumor; Female; Humans; Intestinal Neoplasms; Kidney Failure, Chronic; Octreotide; Radiation Injuries; Yttrium Radioisotopes | 2002 |